Genomic Investigation of Unusual Responders
Studies have shown that tumours from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumours that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumour samples to identify the genetic basis of a patient's exceptional response to chemotherapy.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society